Results 71 - 80 of 92 : Previous 2 3 4 5 6 7 8 9 10 Next
Competition for painkiller patch may prove to be a major pain for the generics maker.
Two drug approvals in one weekend.
Counting the Ways I Love Your Free Cash
Investors are not appreciating Gilead's potential for growing free cash flow.
A small generic-drug maker holds its own.
The integration of Pliva is going along nicely.
Steady revenue growth results in positive income for the quarter.
Is Par Pharmaceutical Settling for Less?
The generic drugmaker avoids going to court in some recent cases.
The generic drug maker is at it again.
Will Pfizer be able to offset the looming loss of Lipitor?
The maker of generic drugs gets sued twice in one week.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK